Americans For Pharma Reform's banner
Americans For Pharma Reform's profile picture

Americans For Pharma Reform

@BustBigPharma • 5,618 subscribers

A grassroots organization exposing the corruption and insane influence of Big Pharma. 1st step: 🚫Banning Pharma TV Ads

Shorts

📍BONITA SPRINGS, FL - Floridians want President Donald J. Trump to keep up the fight against Big Pharma!

📍BONITA SPRINGS, FL - Floridians want President Donald J. Trump to keep up the fight against Big Pharma!

188,768 views

Videos

LIVE
1.2k

Anya Rossi

sweetdream.ai

SweetDream.aiSponsored•Livecam
Streaming Now

Watch Anya Live

Anya is streaming live right now! Join her private show and enjoy exclusive content.

HD live stream
Exclusive private shows
1.2k viewers online

Free preview available • Premium content

Big Pharma shells out $10+ BILLION every year on ads. Their goal? Not to educate consumers, but to buy off the media. Big Pharma knows the networks won't bite the hand that feeds them. 🚨 Add your name to a list of Americans demanding that Congress take action:
0:30
BustBigPharma's profile picture

Big Pharma shells out $10+ BILLION every year on ads. Their goal? Not to educate consumers, but to buy off the media. Big Pharma knows the networks won't bite the hand that feeds them. 🚨 Add your name to a list of Americans demanding that Congress take action:

Americans For Pharma Reform

9,047,585 views • 1 year ago

🏆 “Most Annoying TV Ads” didn’t make the list of award categories, but the obvious winner is: BIG PHARMA Endless predatory ads w/crazy side effects, as Americans pay RECORD $$$ for prescription drugs CONGRESS MUST: 1. Ban Pharma Ads 2. Codify Trump’s 'Most Favored Nation' Plan
0:30
BustBigPharma's profile picture

🏆 “Most Annoying TV Ads” didn’t make the list of award categories, but the obvious winner is: BIG PHARMA Endless predatory ads w/crazy side effects, as Americans pay RECORD $$$ for prescription drugs CONGRESS MUST: 1. Ban Pharma Ads 2. Codify Trump’s 'Most Favored Nation' Plan

Bust Big Pharma

2,269,266 views • 6 months ago

While Americans can’t afford insulin, Big Pharma spends over $10B a year buying off the media and brainwashing you with predatory ads. TV. Internet. Magazines. All infected. They’re not promoting health, they’re pushing dependence. Congress must pull the plug. Ban Pharma Ads!
0:30
BustBigPharma's profile picture

While Americans can’t afford insulin, Big Pharma spends over $10B a year buying off the media and brainwashing you with predatory ads. TV. Internet. Magazines. All infected. They’re not promoting health, they’re pushing dependence. Congress must pull the plug. Ban Pharma Ads!

Bust Big Pharma

4,021,224 views • 11 months ago

🚨 CONGRESS MUST CODIFY PRES. Donald J. Trump's 'MOST FAVORED NATION' POLICY Pres. Trump is reining in Big Pharma and lowering the cost of prescription drugs. Now Congress must follow his lead and take permanent action by codifying Trump's 'Most Favored Nation' policy into law!
0:24
BustBigPharma's profile picture

🚨 CONGRESS MUST CODIFY PRES. Donald J. Trump's 'MOST FAVORED NATION' POLICY Pres. Trump is reining in Big Pharma and lowering the cost of prescription drugs. Now Congress must follow his lead and take permanent action by codifying Trump's 'Most Favored Nation' policy into law!

Bust Big Pharma

595,572 views • 2 months ago

🚨 CONGRESS MUST CODIFY PRES @REALDONALDTRUMP'S 'MOST FAVORED NATION' PLAN INTO LAW! FACT: The U.S. makes up less than 5% of the world's population, but funds 75% of global pharmaceutical profits. Trump's 'Most Favored Nation' Plan lowers drug prices & ends global freeloading!
0:43
BustBigPharma's profile picture

🚨 CONGRESS MUST CODIFY PRES @REALDONALDTRUMP'S 'MOST FAVORED NATION' PLAN INTO LAW! FACT: The U.S. makes up less than 5% of the world's population, but funds 75% of global pharmaceutical profits. Trump's 'Most Favored Nation' Plan lowers drug prices & ends global freeloading!

Bust Big Pharma

1,270,564 views • 7 months ago

The pharmaceutical industry's three largest spending categories: advertising to create demand, executive compensation, and lobbying to protect the system that funds both. Research is what gets cut when a CEO wants a raise. The innovation argument for high drug prices requires research to be the priority. The financial filings show it's the variable.
0:27
BustBigPharma's profile picture

The pharmaceutical industry's three largest spending categories: advertising to create demand, executive compensation, and lobbying to protect the system that funds both. Research is what gets cut when a CEO wants a raise. The innovation argument for high drug prices requires research to be the priority. The financial filings show it's the variable.

Americans For Pharma Reform

253,417 views • 2 months ago

SEC filings should be standard evidence in every drug-pricing conversation. Rob Burgess argues policymakers should compare pharma’s public promises with the legally binding disclosures made to investors—before declaring a deal finished.
1:03
BustBigPharma's profile picture

SEC filings should be standard evidence in every drug-pricing conversation. Rob Burgess argues policymakers should compare pharma’s public promises with the legally binding disclosures made to investors—before declaring a deal finished.

Americans For Pharma Reform

168,411 views • 2 months ago

A temporary deal gives Big Pharma a date to outlast. Durable reform needs a statute with clear coverage, public reporting, enforcement deadlines, and consequences for evasion. Rob Burgess explains how to close the industry’s exit route.
0:22
BustBigPharma's profile picture

A temporary deal gives Big Pharma a date to outlast. Durable reform needs a statute with clear coverage, public reporting, enforcement deadlines, and consequences for evasion. Rob Burgess explains how to close the industry’s exit route.

Americans For Pharma Reform

160,652 views • 2 months ago

AbbVie cut workers, cut research by 29%, gave the CEO a 75% raise, spent billions on advertising, and charged patients prices justified by innovation the company's own financial decisions were actively defunding. When those are the facts on the table, the innovation argument isn't a business case. It's a cover story — and the filings that prove it are public record.
0:36
BustBigPharma's profile picture

AbbVie cut workers, cut research by 29%, gave the CEO a 75% raise, spent billions on advertising, and charged patients prices justified by innovation the company's own financial decisions were actively defunding. When those are the facts on the table, the innovation argument isn't a business case. It's a cover story — and the filings that prove it are public record.

Americans For Pharma Reform

151,154 views • 2 months ago

193 countries looked at pharmaceutical companies running primetime TV ads telling patients to ask their doctor for specific medications and said no. The US and New Zealand said yes. Every country that drew that line also pays dramatically less for the same drugs Americans pay full price for. The two facts have been sitting next to each other since 1997 and the connection between them is not complicated.
0:50
BustBigPharma's profile picture

193 countries looked at pharmaceutical companies running primetime TV ads telling patients to ask their doctor for specific medications and said no. The US and New Zealand said yes. Every country that drew that line also pays dramatically less for the same drugs Americans pay full price for. The two facts have been sitting next to each other since 1997 and the connection between them is not complicated.

Bust Big Pharma

148,961 views • 2 months ago

Big Pharma’s spending ratio reveals what the business is built to maximize. Billions spent on promotion can shape demand, protect familiar brands, and preserve pricing power long after a drug reaches the market.
0:21
BustBigPharma's profile picture

Big Pharma’s spending ratio reveals what the business is built to maximize. Billions spent on promotion can shape demand, protect familiar brands, and preserve pricing power long after a drug reaches the market.

Americans For Pharma Reform

115,629 views • 2 months ago

Five sourced findings raise a basic question: are high drug prices funding discovery, or rewarding the companies best positioned to acquire, market, and extend the life of discoveries made elsewhere? Rob Burgess follows the money behind the innovation defense.
1:13
BustBigPharma's profile picture

Five sourced findings raise a basic question: are high drug prices funding discovery, or rewarding the companies best positioned to acquire, market, and extend the life of discoveries made elsewhere? Rob Burgess follows the money behind the innovation defense.

Americans For Pharma Reform

110,800 views • 2 months ago

Big Pharma keeps using R&D costs to justify high launch prices even after peer-reviewed research found no association between the two. The argument persists because it protects profits and blocks reform. Rob Burgess follows the receipts.
1:02
BustBigPharma's profile picture

Big Pharma keeps using R&D costs to justify high launch prices even after peer-reviewed research found no association between the two. The argument persists because it protects profits and blocks reform. Rob Burgess follows the receipts.

Americans For Pharma Reform

102,084 views • 2 months ago

Every time Scott Gottlieb appears on television to comment on pharmaceutical policy, he's introduced as "former FDA Commissioner." That's accurate. It leaves out that he currently sits on Pfizer's board with fiduciary duties — a legal obligation to act in their financial interest. He ran the agency that regulated Pfizer. The law now describes him as working for Pfizer. One of those facts makes the chyron. The other one rarely does.
0:41
BustBigPharma's profile picture

Every time Scott Gottlieb appears on television to comment on pharmaceutical policy, he's introduced as "former FDA Commissioner." That's accurate. It leaves out that he currently sits on Pfizer's board with fiduciary duties — a legal obligation to act in their financial interest. He ran the agency that regulated Pfizer. The law now describes him as working for Pfizer. One of those facts makes the chyron. The other one rarely does.

Bust Big Pharma

91,119 views • 2 months ago

Scott Gottlieb shaped FDA regulatory philosophy during one of its most consequential periods. He now sits on Pfizer's board — a role with a legal fiduciary obligation to act in Pfizer's financial interest. He still appears regularly as a pharmaceutical policy commentator. Sometimes the Pfizer disclosure makes it in. Often the introduction just says "former FDA commissioner." Those are two very different introductions for the same person, and whoever's writing the chyron knows the difference.
1:00
BustBigPharma's profile picture

Scott Gottlieb shaped FDA regulatory philosophy during one of its most consequential periods. He now sits on Pfizer's board — a role with a legal fiduciary obligation to act in Pfizer's financial interest. He still appears regularly as a pharmaceutical policy commentator. Sometimes the Pfizer disclosure makes it in. Often the introduction just says "former FDA commissioner." Those are two very different introductions for the same person, and whoever's writing the chyron knows the difference.

Americans For Pharma Reform

88,878 views • 3 months ago

🚨 EXPOSED: Big Pharma's media BUY OFF explained to the American people.
0:31
BustBigPharma's profile picture

🚨 EXPOSED: Big Pharma's media BUY OFF explained to the American people.

Bust Big Pharma

264,853 views • 1 year ago

The pharmaceutical industry calls it a patent cliff — the moment exclusivity expires and generic competition drives cancer drug prices down. A CEO told investors on an earnings call that the company's deliberate strategy is to turn that cliff into a hill, extending monopoly-level pricing well past the point the patent system was designed to allow. He described it as a value creation strategy for shareholders. The patients paying monopoly prices on cancer drugs are the ones creating that value.
0:34
BustBigPharma's profile picture

The pharmaceutical industry calls it a patent cliff — the moment exclusivity expires and generic competition drives cancer drug prices down. A CEO told investors on an earnings call that the company's deliberate strategy is to turn that cliff into a hill, extending monopoly-level pricing well past the point the patent system was designed to allow. He described it as a value creation strategy for shareholders. The patients paying monopoly prices on cancer drugs are the ones creating that value.

Americans For Pharma Reform

107,354 views • 5 months ago

🚨 BREAKING: PRESIDENT Donald J. Trump CRACKING DOWN ON BIG PHARMA ADS! Secretary Kennedy explains memorandum signed by Pres. Trump to force Big Pharma to fully disclose ALL HEALTH RISKS in ads. FDA ordered to go after "misleading" drug ads. Next up: BANNING Big Pharma Ads on TV!
2:23
BustBigPharma's profile picture

🚨 BREAKING: PRESIDENT Donald J. Trump CRACKING DOWN ON BIG PHARMA ADS! Secretary Kennedy explains memorandum signed by Pres. Trump to force Big Pharma to fully disclose ALL HEALTH RISKS in ads. FDA ordered to go after "misleading" drug ads. Next up: BANNING Big Pharma Ads on TV!

Americans For Pharma Reform

233,791 views • 1 year ago